Patrick Enright interview

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

please check before submitting

Mobile number:

What is your role?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

Investing in orphan drug companies

An interview with Patrick Enright, Managing Director, Longitude Capital

Following the growth of the orphan drug industry and the increasing appetite of investors, we interviewed Patrick Enright, Managing Director of Menlo Park based venture capital firm Longitude Capital to discuss some of the current challenges in investing in orphan drug companies.

The transcript of his interview is included in this document.

Download the interview to learn more about:

What stage of development are investors looking for
Deals models
How investors are assessing clinical risk
Challenges and opportunities of publicly traded companies
How to assess market potential

Patrick Enright interview

information we require

please check before submitting

Investing in orphan drug companies

An interview with Patrick Enright, Managing Director, Longitude Capital